Incidence of Major Adverse Cardiovascular and Cerebrovascular Events in Chinese Patients Undergoing Percutaneous Coronary Interventions with Iodixanol - A Non Interventional Post-Authorisation Study

Trial Profile

Incidence of Major Adverse Cardiovascular and Cerebrovascular Events in Chinese Patients Undergoing Percutaneous Coronary Interventions with Iodixanol - A Non Interventional Post-Authorisation Study

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 May 2016

At a glance

  • Drugs Iodixanol (Primary)
  • Indications Cardiovascular disorders; Cerebrovascular disorders
  • Focus Adverse reactions
  • Acronyms IMPERIAL
  • Sponsors GE Healthcare
  • Most Recent Events

    • 03 May 2016 Status changed from not yet recruiting to recruiting.
    • 29 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top